Anfibatide Phase Ib-IIa Clinical Trial
A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI).
Sponsor: Lee's Pharmaceutical Limited
Listed as NCT01585259, this PHASE1/PHASE2 trial focuses on Non-ST Segment Elevation Myocardial Infarction and remains completed. Sponsored by Lee's Pharmaceutical Limited, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lee's Pharmaceutical Limited
For direct contact, visit the study record on ClinicalTrials.gov .